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Abstract: Non-alcoholic steatohepatitis (NASH) represents a risk factor for the 
development of hepatocellular carcinoma (HCC) and is characterized by quantitative and 
qualitative changes in hepatic lipids. Since elongation of fatty acids from C16 to C18 has 
recently been reported to promote both hepatic lipid accumulation and inflammation we 
aimed to investigate whether a frequently used mouse NASH model reflects this clinically 
relevant feature and whether C16 to C18 elongation can be observed in HCC development. 
Feeding mice a methionine and choline deficient diet to model NASH not only increased 
total hepatic fatty acids and cholesterol, but also distinctly elevated the C18/C16 ratio, 
which was not changed in a model of simple steatosis (ob/ob mice). Depletion of  
Kupffer cells abrogated both quantitative and qualitative methionine-and-choline deficient  
(MCD)-induced alterations in hepatic lipids. Interestingly, mimicking inflammatory  
events in early hepatocarcinogenesis by diethylnitrosamine-induced carcinogenesis (48 h) 
increased hepatic lipids and the C18/C16 ratio. Analyses of human liver samples from 
patients with NASH or NASH-related HCC showed an elevated expression of the elongase 
ELOVL6, which is responsible for the elongation of C16 fatty acids. Taken together, our 
findings suggest a detrimental role of an altered fatty acid pattern in the progression of 
NASH-related liver disease. 
Keywords: diethylnitrosamine; ELOVL6; HCC; hepatic steatosis; leptin deficiency; MCD; 
non-alcoholic fatty liver disease (NAFLD); ob/ob 
 
1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is regarded as the most common liver disorder [1]. 
Although NAFLD is often an asymptomatic disease and therefore difficult to detect, the prevalence 
appears to be around 20%–35% of the adult population in Western countries [2–4]. NAFLD/NASH 
(non-alcoholic steatohepatitis) strongly correlates with characteristics of the metabolic syndrome, such 
as obesity and diabetes mellitus, and NAFLD/NASH [5–7]. Liver pathogenesis of NAFLD is widely 
believed to start with simple steatosis, which is characterized by excessive lipid accumulation [2,8]. 
The progression from simple steatosis to NASH is mediated by the release of inflammatory  
cytokines [9] and can result in hepatic cirrhosis and finally in hepatocellular carcinoma (HCC) [10]. 
Due to this inflammatory environment 4% to 27% of individuals with NASH and cirrhosis [11] 
develop HCC. 
There is increasing evidence that in steatosis besides the total amount of accumulated lipids the 
composition of lipids has an impact on pathophysiology [12,13]. In fact, human NAFLD is 
characterized by numerous changes in hepatic lipid composition and free fatty acid ratios [14,15]. 
Viral hepatitis has also been described to lead to strongly altered hepatic lipid content and  
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composition [16–19]. In HCC a decreased stearic acid (C18:0) to oleic acid (C18:1) ratio compared to 
normal tissue has been reported, suggesting the importance of desaturation in HCC development [20]. 
Regarding changes in hepatic fatty acid pattern it is important to note that the ELOVL fatty acid 
elongase 6 (ELOVL6), which catalyzes the elongation of C16 to C18 fatty acids [21], has been shown 
to promote NASH [22,23]. A role of ELOVL6 in murine NASH-related HCC has recently been 
suggested, but still remains unclear in human NASH-associated HCC [23]. 
The aims of our study were to investigate the occurrence of fatty acid elongation in lipid 
metabolism in different NAFLD mouse models and to elucidate its relevance in human NASH and 
NASH-associated HCC. 
2. Results and Discussion 
2.1. Fatty Acid Elongation in Murine Non-Alcoholic Steatohepatitis (NASH) Is Kupffer Cell Dependent 
Fatty acid elongation plays a role in murine and human NASH development [22,23]. Feeding mice 
a methionine-choline deficient diet (MCD) led to increased total fatty acid and cholesterol levels and 
profound inflammation (Figure 1A,B). Having a closer look at the composition of the fatty acids,  
we observed that the chain length of fatty acids was different in MCD-fed livers compared to tissues 
from a control diet: NASH livers exhibited an increased ratio of C18 to C16 fatty acids (Figure 1B). 
Increased ELOVL6 mRNA expression has been observed in NASH animal models, such as  
low-density lipoprotein receptor knockout animals fed a western type diet [23] or a fructose diet [24]. 
In order to study whether this increased fatty acid elongation from C16 to C18 could also be observed 
in simple steatosis we investigated the well-established leptin-deficiency (ob/ob) mouse model [24,25]. 
As expected, livers of ob/ob mice showed excessive hepatic lipid accumulation compared to lean 
controls (Figure 1C,D). However, no distinct inflammation was observed and the ratio of C18 to C16 
fatty acids was not changed compared to wild-type animals (Figure 1D). Adipose tissue of ob/ob mice 
is known to show inflammation [26]. Concordantly, adipose tissue macrophages of ob/ob mice exhibit 
increased ELOVL6 mRNA expression [27]. Another study reported increased hepatic ELOVL6 
expression in older ob/ob mice, whereby some of the animals were in a fasted condition [28]. The 
study does not contain any information on fatty acid composition. 
Leroux et al. reported that lipid storage by Kupffer cells correlates with a pro-inflammatory 
phenotype in NASH [29]. In order to clarify whether the altered fatty acid elongation in murine  
NASH is due to co-existing inflammation, we depleted Kupffer cells by clodronate liposomes.  
This intervention is known to attenuate inflammatory and metabolic events in the MCD model [30].  
In line with these findings we observed a strong decrease of hepatic lipid accumulation after Kupffer 
cell depletion (Figure 2A,B). Besides hepatocytes also macrophages are known to express ELOVL6 [27], 
which was shown to be relevant for lipid storage [31]. After Kupffer cell depletion the MCD-induced 
changes in C18 to C16 fatty acids and cholesterol were completely abrogated (Figure 2A,B). Kupffer cell 
depletion was confirmed by immunohistochemical F4/80 staining (Figure 2A). 
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Figure 1. Non-alcoholic steatohepatitis (NASH), but not non-alcoholic fatty liver disease 
(NAFLD), is accompanied by elevation of C18 over C16. (A) Representative liver sections 
stained with hematoxylin-eosin (HE) from animals fed with either a methionine-choline 
deficient (MCD) or a control (crtl) diet for 3 weeks (original magnification 200×). Arrows 
denote inflammatory foci; (B) Sum of all hepatic fatty acids, hepatic cholesterol, and ratio 
of hepatic C18/C16 fatty acids of MCD fed animals compared to ctrl were analyzed by 
GC-MS (gas chromatography-mass spectrometry) (n = 9–10); and (C,D) Representative  
HE-stained liver sections (C), hepatic fatty acids as well as hepatic cholesterol, and ratio of 
hepatic C18/C16 fatty acids (D) of ob/+ and ob/ob mice (n = 8). 
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Figure 2. Kupffer cell depletion abrogated elevation of C18 over C16. (A) Representative 
liver sections immunohistologically stained against F4/80 as Kupffer cell marker from 
animals fed with the respective diet for 3 weeks with simultaneous administration of 
clodronate (clo) or empty (sham) liposomes (original magnification 200×); and (B,C) Increase 
of the sum of all hepatic fatty acids, hepatic cholesterol (B), and ratio of hepatic C18/C16 
fatty acids (C) of MCD fed animals treated with clodronate (clo) or empty (sham) liposomes 
compared to ctrl analyzed by GC-MS (n = 9–10). 
 
2.2. Role of Fatty Acid Elongation in NASH-Related Hepatocellular Carcinoma (HCC) and  
Human NASH 
To further investigate the role of fatty acid elongation in hepatocarcinogenesis, we used  
short-term (48 h) treatment with the carcinogen diethylnitrosamine (DEN) to model early 
inflammatory events associated with hepatocarcinogenesis [32,33]. In fact, we histologically observed 
inflammatory foci in the livers exposed to DEN (Figure 3A). Little is known about increased lipid 
accumulation after DEN treatment: Histologically detected hepatic lipid deposition by DEN was 
reported in fish (Oryzias lapites) [34,35]. Changes in the lipid composition have been reported for 
cancerous tissues compared to normal tissue in DEN-induced hepatocarcinogenesis [36–38], but not  
in the precancerous short-term protocol. We observed that inflammatory events were paralleled by 
distinct metabolic alterations similar to the murine NASH model: fatty acids, cholesterol levels, and 
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the C18/C16 ratio were elevated upon 48 h DEN treatment (Figure 3B). This short-term model might 
therefore resemble NASH-related hepatocarcinogenesis. In later stages of DEN-induced carcinogenesis 
and during tumor progression we observed that fatty acid elongation was rather repressed [39].  
This can be explained by the fact that the long-term DEN model predominantly acts via genotoxic 
effects of the carcinogen and therefore no NASH-related HCCs are induced. 
Figure 3. (A) Representative liver sections stained with HE from animals treated with 
DEN (DEN) compared to untreated control (crtl) (original magnification 200×). Arrows 
denote inflammatory foci; (B) Sum of all fatty acids, hepatic cholesterol, and ratio of 
C18/C16 fatty acids of DEN treated animals compared to untreated control (ctrl) are 
displayed (n = 6–15); (C,D) Expression of ELOVL6 in human NASH (n = 18) compared 
to steatosis (n = 14) (GSE48452) (n.s. = not statistically significant) (C) as well as healthy 
control samples (n = 8 for NASH; n = 7 for control; GSE37031) (D); and (E) ELOVL6 
mRNA expression in human NASH-related HCC samples (NASH-HCC) (n = 6) compared 
to HCC with mixed etiology (mixed HCC) (n = 26) [40]. Expression of tumor tissues was 
normalized to matched normal liver tissue (matched control). 
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Figure 3. Cont. 
 
In order to study the relevance of increased fatty acid elongation in human NASH and human 
NASH-related HCC, we analyzed the hepatic mRNA expression of the enzyme ELOVL6, which is 
responsible for the elongation of C16 fatty acids. We observed increased levels of ELOVL6 in NASH 
versus steatosis samples (GSE48452 [41]) (Figure 3C) as well as in NASH compared to healthy 
control tissues (GSE37031 [42]) (Figure 3D). Interestingly, expression of ELOVL6 was also altered  
in NASH-associated HCCs compared to HCC tissues of mixed etiology (Figure 3E): human  
NASH-related HCCs express increased levels of ELOVL6, indicating fatty acid elongation to play a 
critical role in this particular HCC subtype. 
3. Experimental Section  
3.1. Animals 
All animal procedures were performed in accordance with the local animal welfare committee 
(#13/2009, 09/06/2009; #34/2010, 15/11/2010; Landesamt für Soziales, Gesundheit und 
Verbraucherschutz Saarland). Mice were kept under stable conditions regarding temperature, humidity, 
food delivery, and 12 h day/night rhythm. At the age of 3 weeks mice (DBA2/Bl6/J background) were 
fed either a methionine-choline deficient (MCD) or a methionine-choline supplemented control (crtl) 
diet for 3 weeks. Intraperitoneal clodronate or empty liposome injections [43] were started two days 
prior to MCD or control diet and repeated every five days to ensure Kupffer cell depletion. Leptin 
deficient mice ob/ob (Bl6:Cg-Lepob/J) and lean control mice (ob/+) were obtained from Charles River 
and sacrificed at an age of 10 weeks. DEN treatment of mice (DBA2/Bl6/J background) on regular 
chow was performed by a single intraperitoneal injection of 100 mg/kg body weight at the age of  
2.5 weeks. Mice were sacrificed 48 h after DEN injection. Animals of all experimental groups were 
sacrificed in a non-fasted state. 
3.2. Human Liver Tissue 
Paraffin-embedded liver samples from randomly selected pseudonymized HCC patients who 
underwent liver resection at the Saarland University Medical Center between 2005 and 2010 were 
obtained as described previously [40]. The study protocol was approved by the local Ethics Committee 
Int. J. Mol. Sci. 2014, 15 5769 
 
 
(#47/07). Samples had a mixed etiology including NASH, alcoholic liver disease, viral hepatitis, 
hemochromatosis, porphyria, and cryptogenic [40]. 
3.3. Fatty Acid Measurement by Gas Chromatography-Mass Spectrometry (GC-MS) 
Murine liver samples were lyophilized and analyzed according to Bode et al. [44]. In short, 
lyophilized samples were dissolved in a mixture of 500 μL methanol/toluene/sulfuric acid  
(50:50:2, v/v/v) and incubated at 55 °C overnight. Subsequently, 400 μL of a 0.5 M NH4CO3, 2 M KCl 
solution were added and samples were centrifuged. The organic phase was transferred into a new glass 
vial, derivatized with 25 µL N-methyl-N-(trimethylsilyl)trifluoroacetamide at 37 °C for 1 h. Fatty acid 
separation was performed on an Agilent 6890N gas chromatograph coupled to an Agilent 5973N mass 
selective detector and equipped with a non-polar J&WDB-5HT capillary column (Agilent Technologies, 
Böblingen, Germany). The column temperature was kept at 130 °C for 2.5 min, increased to 240 °C at 
a rate of 5 °C/min, and then ramped to 300 °C at 30 °C/min, and held at 300 °C for 5 min. Helium was 
used as the carrier gas at a flow rate of 1 mL/min. The mass selective detector was operated in scan 
mode, average spectra were acquired in the m/z range of 40–700 m/z and were recorded at a scan speed 
of 2.24 scans/s. Scan control, data acquisition, and processing were performed by MSD ChemStation 
(Agilent Technologies, Böblingen, Germany) and AMDIS software based on the fragmentation 
patterns and retention time, in comparison with the reference standards Supelco 37 Component FAME 
Mix (Sigma-Aldrich, Taufkirchen, Germany), and NIST 08 library. Methyl-nonadecanoate (74208, 
Sigma-Aldrich, Taufkirchen, Germany) was used as an internal standard. The method detects both free 
and bound fatty acids. 
3.4. Histochemistry and Immunohistochemistry 
Hematoxylin-eosin staining of paraffin-embedded tissues was performed as previously  
reported [45,46]. Immunohistochemical F4/80 detection was achieved using the Vectastain Peroxidase 
Elite ABC kit/DAB with anti-F4/80 antibody (AbD Serotec, Puchheim, Germany) 1:1000 overnight at 
4 °C. Epitopes were demasked with citrate buffer pH 6.0 for 10 min in a waterbath at 95 °C. 
3.5. Analysis of the Public Gene Omnibus (GEO) Datasets 
Datasets GSE48452 and GSE37031 [41,42] normalized using log2-RMA and log2-GCRMA 
respectively, were downloaded from Gene omnibus (GEO) [47]. Dataset GSE48452 with samples 
from different stages of NAFLD contained 18 NASH and 14 steatosis samples while dataset 
GSE37031 included 8 NASH and 7 control samples. The statistical significance was determined by 
Kolmogorov-Smirnov test. 
3.6. Statistical Analysis 
Results are expressed as means ± SEM. The statistical significance was determined by independent 
two-sample t-test. Expression data of human tissues were analyzed using Mann-Whitney U tests.  
The results were considered as statistically significant when p value was less than 0.05. 
  




In the present study, we identified that NASH-induced fatty acid elongation is an  
inflammation-associated pathophysiological step in liver disease. Furthermore, the fatty acid elongase 
ELOVL6 is elevated in human NASH and NASH-related HCC. 
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